Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS

• Published in: Journal for immunotherapy of cancer 2023-11, Vol.11 (11), p.e007790
• Main Authors: Zhang, Man, Long, Xiaolu, Xiao, Yi, Jin, Jin, Chen, Caixia, Meng, Jiao, Liu, Wanying, Liu, Aichun, Chen, Liting
• Format: Article
• Language: English
• Subjects: Anticoagulants; Antigens; Bacterial infections; Biomarkers; Cancer; Cells; Chemotherapy; Clinical trials; Cytokine Release Syndrome; Cytokines; Humans; Immunotherapy; Immunotherapy Biomarkers; Lymphocytes; Neoplasms; Neutropenia; Neutrophils; Patients; Receptors, Antigen, T-Cell - genetics; T-Lymphocytes; Toxicity; Variables
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2023-007790

BackgroundChimeric antigen receptor (CAR) T cell therapy is an advanced and effective immunotherapy for relapsed or refractory B-cell malignancies. High expansion of CAR T cells in vivo and durable antitumor activity indicate a persistent therapeutic response. However, this treatment is linked to a high frequency of adverse events, such as cytokine release syndrome (CRS), which affects its efficacy and can even be life-threatening. At present, a variety of markers associated with clinical response and treatment toxicity after CAR T cells infusion have been reported. Although these biomarkers can act as effective indicators reflecting CAR T cells expansion as well as CRS, they fail to predict the expansion rate of CAR T cells. Hence, further investigation is urgent to find a new biomarker to fill this void.MethodsWe analyzed the association between the absolute neutrophil count (ANC) and CAR expansion and CRS in 45 patients with B-cell malignancies from two clinical trials. We proposed that ANC could be a practical biomarker for CAR T cells expansion and CRS, and conducted a feasibility analysis on its predictive ability.ResultsIn this study, 17 B-cell hematological malignancy patients with anti-B-cell maturation antigen CAR-treated and 28 with CAR19/22 T-cell-treated were enrolled and divided into an ANC-absence group and an ANC-presence group. The results showed that ANC absence correlated positively with CAR expansion and the expansion rate. The ANC can be used as a predictive marker for CAR T cells expansion. Moreover, the patients with ANC absence experienced a more severe CRS, and ANC performed a predictive ability for CRS. In addition, the peak serum concentration of several cytokines involved in CRS was higher in patients with ANC absence.ConclusionThus, we suggest ANC as an evaluative and predictive biomarker for CAR expansion and CRS during CAR T cell therapy, which can help to maximize clinical efficacy, reduce treatment-related toxicity and prolong survival.